治疗阿尔茨海默病药物的临床研究进展

摘要

阿尔茨海默病(Alzheimer's disease,AD)发病机制非常复杂,主要与β-淀粉样蛋白(β-amyloid,Aβ)、中枢递质异常等多种因素相关,治疗十分困难.目前获美国FDA批准上市的药物仅5种,处在临床研究阶段的有77种.抗AD药物的临床研究一直处于不成功的过程,本文对已上市及处于临床研究的药物进行了综述,并对近3年来药物研究的变化进行了分析.%Alzheimer's disease (AD) pathogenesis is complex which is mainly related to the beta-amyloid,central neurotransmitter abnormalities and many other factors.AD treatment is very difficult.Until now the United States Food and Drug Administration (FDA) approved only five drugs and there are seventy-seven drugs in clinical research stage.Studies of anti-AD drugs have been unsuccessful.In this paper,the drugs already on the market and in clinical research stage are reviewed and the changes in drug research in the last three years are analyzed.